Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Olivier Sitbon (Le Kremlin Bicêtre, France), Olivier Sitbon, Richard Channick, Kelly Chin, Aline Frey, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Marius M. Hoeper, Irene Lang, Franck-Olivier Le Brun, Vallerie McLaughlin, Ralph Preiss, Lewis J. Rubin, Gérald Simmonneau, Victor Tapson, Sean Gaine
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Session: Pulmonary hypertension: new treatment insights
Session type: Oral Presentation
Number: 4995
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Olivier Sitbon (Le Kremlin Bicêtre, France), Olivier Sitbon, Richard Channick, Kelly Chin, Aline Frey, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Marius M. Hoeper, Irene Lang, Franck-Olivier Le Brun, Vallerie McLaughlin, Ralph Preiss, Lewis J. Rubin, Gérald Simmonneau, Victor Tapson, Sean Gaine. Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results. Eur Respir J 2015; 46: Suppl. 59, 4995
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: